AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Moderna to Present Data on mRNA Therapeutics at ICIEM 2025
ByAinvest
Tuesday, Sep 2, 2025 7:17 am ET1min read
Moderna has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism. The presentations will focus on its propionic acidemia, methylmalonic acidemia, and Glycogen Storage Disease Type 1a programs. This is the first time Moderna will present data at a scientific congress for MMA and GSD1a.
Moderna, Inc. (NASDAQ: MRNA) has announced that five abstracts on its investigational mRNA therapeutics will be presented at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM). The presentations will focus on the company's propionic acidemia (PA), methylmalonic acidemia (MMA), and Glycogen Storage Disease Type 1a (GSD1a) programs, marking the first time Moderna will present data at a scientific congress for MMA and GSD1a [1].The presentations, scheduled for September 2-6, 2025, in Kyoto, Japan, include three oral presentations and two poster presentations. The oral presentations will cover clinical burden data for propionic acidemia in Japan, interim data from Phase 1/2 studies for MMA and GSD1a, and final results from the dose-escalation cohorts of the mRNA-3927-P101 study for PA. The poster presentations will feature model-informed dose selection for a pivotal MMA study and interim data from the Phase 1/2 Ba1ance Study for GSD1a [2].
These presentations demonstrate Moderna's strategic expansion into rare diseases, leveraging its mRNA platform technology beyond vaccines into therapeutics. The company is addressing significant unmet medical needs with limited treatment options. The presentations will provide validation and visibility for these development programs within the scientific and medical communities specialized in metabolic disorders.
Moderna's diversification into rare diseases is a strategic move that could open up new revenue streams beyond its established COVID-19 vaccine business. While these programs are still in early to mid-stage clinical development, their advancement represents an important diversification of Moderna's pipeline.
References:
[1] https://www.stocktitan.net/news/MRNA/moderna-announces-data-to-be-presented-at-the-2025-international-3ddgvnfi7m8o.html
[2] https://www.newswire.com/news/moderna-announces-data-to-be-presented-at-the-2025-international-congress-of
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet